Jazz Pharmaceuticals PLC (JAZZ) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]
Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ)
Last jazz pharmaceuticals plc - ordinary shares earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
jazzpharma.com
Company Research
Source: Yahoo! Finance
Cash from Operations: Approximately $400 million in Q3, roughly $1 billion year-to-date. Cash and Cash Equivalents: $2.6 billion. Xywav Net Product Sales: $388 million, 17% year-over-year growth. Epidiolex Net Product Sales: $252 million, 18% year-over-year growth. Oncology Revenue: $285 million, 9% growth year-over-year. Rylaze Product Sales: $99 million, a 6% decrease year-over-year. Zepzelca Net Product Sales: $86 million, 10% year-over-year growth. Operating Margin: Approximately 49% for the quarter. Full Year Revenue Guidance: $4 billion to $4.1 billion. Neuroscience Revenue Guidance: $2.825 billion to $2.925 billion. Oncology Revenue Guidance: Lowered by $20 million to $1.08 billion to $1.13 billion. R&D Guidance: Lowered by $20 million to $790 million to $830 million. Effective Tax Rate Guidance: 10% to 12%. Adjusted Net Income Guidance: $1.275 billion to $1.35 billion. Warning! GuruFocus has detected 7 Warning Signs with JAZZ. Release Date: Novem
Show less
Read more
Impact Snapshot
Event Time:
JAZZ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JAZZ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JAZZ alerts
High impacting Jazz Pharmaceuticals plc - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
JAZZ
News
- Jazz (JAZZ) Reliance on International Sales: What Investors Need to Know [Yahoo! Finance]Yahoo! Finance
- Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target lowered by analysts at TD Cowen from $200.00 to $195.00. They now have a "buy" rating on the stock.MarketBeat
- Jazz Tops Q3 Earnings & Sales Estimates, Raises '24 EPS View [Yahoo! Finance]Yahoo! Finance
- Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $207.00 price target on the stock.MarketBeat
- Compared to Estimates, Jazz (JAZZ) Q3 Earnings: A Look at Key Metrics [Yahoo! Finance]Yahoo! Finance
JAZZ
Earnings
- 11/6/24 - Beat
JAZZ
Sec Filings
- 11/12/24 - Form SC
- 11/8/24 - Form 144
- 11/7/24 - Form 10-Q
- JAZZ's page on the SEC website